NOV 5, 2026 · REVIEW
Reduced-dose versus label-dose anti-PD-1 therapy in advanced cancer: a systematic review and meta-analysis of randomised and cohort studies
Stemedicine
Background: This review assessed whether reduced-exposure anti-PD-1 therapy (a dose below label, or an interval beyond label) is non-inferior to label dosing for overall survival i